Jerry R. Mendell Center for Gene Therapy

Learn more about director Kevin Flanigan, MD, and the team of principal investigators at the Jerry R. Mendell Center for Gene Therapy.

Learn more about muscular dystrophy research and other areas of focus at the Jerry R. Mendell Center for Gene Therapy and see the latest featured research and projects to come out of our center.

The FDA has issued an accelerated approval for a second gene therapy developed at Nationwide Children's Hospital, bringing hope to children with Duchenne muscular dystrophy.

Nationwide Children’s Hospital is not only home to world-class neuromuscular research and clinical services, it’s also the hub of an extraordinary and collaborative training environment.

The Myology Course at Nationwide Children's is the only U.S. workshop of its kind, featuring a mix of basic and clinical science lectures followed by specific training in either clinical treatment protocols or basic science laboratory techniques.

The OSU and Nationwide Children's Muscle Group brings together investigators with diverse research interests in skeletal muscle, cardiac muscle, and neuromuscular biology.

Learn more about ongoing clinical trials and other clinical research related to muscular dystrophies and other disorders.

The Nationwide Children’s Hospital Center for Gene Therapy is committed to the development of therapies for ultrarare disorders, and to engaging with the patient and family communities affected by these disorders.

The Bradbury Laboratory is dedicated to understanding disease mechanisms and developing therapeutic approaches for rare, pediatric neurodegenerative disorders.

Under the direction of Kevin Flanigan, MD, the Flanigan Lab focuses on the genetic and molecular characterization of inherited neuromuscular diseases, and toward the development of therapies directed toward these diseases.

Under the direction of Paul Martin, PhD, the Martin Lab's goal is to develop curative therapies for children with neuromuscular and lysosomal disorders, including forms of muscular dystrophy, lysosomal storage disorders, myopathies and motor neuron diseases.

Under the direction of Stefan Nicolau, MD, the Nicolau Lab aims to further the translational development of gene editing therapies for muscle disorders, with a particular emphasis on genetic mutations that require insertion of hundreds or thousands of base pairs into genomic DNA.

Under the direction of Afrooz Rashnonejad, MSc, PhD, the Rashnonejad Lab focuses on developing adeno-associated virus (AAV)-based gene therapies for neuromuscular and neurodegenerative diseases.

Under the direction of Nizar Saad, MSc, PhD, the Saad Lab conducts cutting-edge research to understand the causes of genetic disorders, including neuromuscular diseases, and develops innovative techniques to diagnose, treat and cure these conditions.